Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,688
  • Shares Outstanding, K 22,590
  • Annual Sales, $ 14,660 K
  • Annual Income, $ 6,970 K
  • 36-Month Beta 0.76
  • Price/Sales 7.66
  • Price/Cash Flow N/A
  • Price/Book 1.63

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.58 +2.62%
on 07/16/18
5.97 -21.27%
on 06/22/18
-0.24 (-4.86%)
since 06/15/18
3-Month
4.04 +16.34%
on 05/04/18
6.35 -25.98%
on 05/17/18
+0.39 (+9.05%)
since 04/17/18
52-Week
1.15 +308.70%
on 08/29/17
6.35 -25.98%
on 05/17/18
+2.92 (+164.04%)
since 07/17/17

Most Recent Stories

More News
Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10

Suppresses Inflammation and Immune Activation Without Lymphocyte Stimulation

APVO : 4.70 (+2.40%)
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

ARWR : 15.89 (+0.57%)
APVO : 4.70 (+2.40%)
Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue

APVO : 4.70 (+2.40%)
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 4.70 (+2.40%)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?

On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.

ADVM : 5.20 (-0.38%)
HZNP : 17.02 (-0.29%)
APVO : 4.70 (+2.40%)
CLVS : 45.98 (+0.09%)
What's in the Cards for Inovio (INO) This Earnings Season?

Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

ADVM : 5.20 (-0.38%)
ARRY : 17.15 (+0.70%)
APVO : 4.70 (+2.40%)
INO : 4.22 (+2.18%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

CLDX : 0.51 (unch)
ARRY : 17.15 (+0.70%)
APVO : 4.70 (+2.40%)
BMY : 56.46 (+0.05%)
What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

ARRY : 17.15 (+0.70%)
APVO : 4.70 (+2.40%)
JNJ : 129.02 (+3.47%)
GERN : 3.58 (+4.07%)
What's in the Cards for Merrimack (MACK) in Q1 Earnings?

Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

ADVM : 5.20 (-0.38%)
ARRY : 17.15 (+0.70%)
APVO : 4.70 (+2.40%)
MACK : 5.32 (+0.38%)
Aptevo Therapeutics Announces IND Submission for APVO436

New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing

APVO : 4.70 (+2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 5.10
1st Resistance Point 4.85
Last Price 4.70
1st Support Level 4.46
2nd Support Level 4.32

See More

52-Week High 6.35
Last Price 4.70
Fibonacci 61.8% 4.36
Fibonacci 50% 3.75
Fibonacci 38.2% 3.14
52-Week Low 1.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar